Background

Henoch-Schönlein purpura (IgA vasculitis) nephritis shares pathogenic overlap with IgA nephropathy, yet clinicians lack early biomarkers for tubulointerstitial inflammation — the histological compartment most predictive of long-term renal outcomes. Current monitoring relies on proteinuria and creatinine, both late indicators of established injury.

Gasdermin D (GSDMD) is the executioner of canonical pyroptosis downstream of NLRP3 and caspase-1. Upon cleavage, the N-terminal fragment (GSDMD-NT) forms membrane pores in monocytes and macrophages, releasing IL-1β and IL-18 while generating pyroptotic cell debris. Galactose-deficient IgA1 immune complexes deposited in the mesangium activate complement and recruit tubulointerstitial macrophages that undergo NLRP3-dependent pyroptosis, releasing GSDMD-NT fragments into circulation.

Hypothesis

Serial measurement of serum GSDMD-NT concentration combined with flow cytometric quantification of circulating pyroptotic monocytes (Annexin V+/PI+/Caspase-1 FLICA+ CD14+ cells) will predict tubulointerstitial inflammation severity in IgA vasculitis nephritis 6–14 weeks before serum creatinine elevation, with an AUC >0.82 for distinguishing T1-T2 from T0 tubulointerstitial scores on the Oxford MEST-C classification.

Mechanistic Rationale

1. GSDMD-NT as a proximal pyroptosis readout: Unlike IL-1β (which has multiple upstream activators), GSDMD-NT directly reflects pyroptotic pore formation. Its serum half-life (~4 hours) makes serial kinetics informative of ongoing tissue pyroptosis rather than cumulative damage.
2. Pyroptotic monocyte spillover: Renal tubulointerstitial macrophage pyroptosis generates cellular debris and inflammatory mediators that recruit circulating monocytes. A fraction of these monocytes undergo priming and early pyroptotic commitment in the periphery, detectable by caspase-1 FLICA positivity before full membrane rupture.
3. Temporal dynamics: The GSDMD-NT trajectory slope (rate of increase over 2-week intervals) captures accelerating pyroptotic burden before sufficient tubular damage accumulates to impair GFR.

Testable Predictions

• P1: In a prospective cohort of IgA vasculitis patients (n ≥ 80), bi-weekly serum GSDMD-NT measurements will show a rising slope ≥ 2 standard deviations above baseline 6–14 weeks before creatinine exceeds 1.3× baseline.
• P2: The combined GSDMD-NT slope + pyroptotic monocyte percentage model will achieve AUC > 0.82 for T1-T2 tubulointerstitial score on protocol biopsy, outperforming proteinuria alone (expected AUC ~0.65).
• P3: GSDMD-NT kinetics will correlate with tubulointerstitial macrophage density (CD68+ cells/HPF, r > 0.55) but NOT with mesangial hypercellularity (M0 vs M1), confirming compartment specificity.
• P4: Patients treated with disulfiram (a GSDMD pore inhibitor) or colchicine (indirect NLRP3 suppression) will show attenuated GSDMD-NT slopes, providing pharmacological validation.

Limitations

• GSDMD-NT ELISA assays are research-grade with variable inter-laboratory reproducibility; standardization is required before clinical deployment.
• Pyroptotic monocyte flow cytometry requires fresh samples processed within 4 hours, limiting multicenter feasibility.
• IgA vasculitis nephritis has heterogeneous trajectories; some patients develop crescentic disease (C1-C2) driven by distinct pathways not captured by this pyroptosis-centric model.
• Confounding by infections (which also activate NLRP3/GSDMD) must be controlled via concurrent procalcitonin and CRP monitoring.

Clinical Significance

Early detection of tubulointerstitial inflammation would enable preemptive immunosuppression escalation (e.g., mycophenolate addition) before irreversible fibrosis, potentially reducing progression to CKD stage 3+ in IgA vasculitis nephritis by 20–35%. The GSDMD-NT pathway also identifies patients who may benefit from emerging pyroptosis-targeted therapies (disulfiram repurposing, GSDMD-NT monoclonal antibodies in preclinical development).

LES AI • DeSci Rheumatology